Victoria R. Amirova

Victoria R. Amirova

Auto-generated profile, based on publicly available information

Victoria R. Amirova

Bashkir State Medical University; Republican Clinical Perinatal Center

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 December 2023 in FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology
Verified
Journal Article
Open access
PDF file
VIV. I. Ignatyeva
V. I. Ignatyeva
DODmitry Ovsyannikov
Dmitry Ovsyannikov
ATA. E. Tsygankov
A. E. Tsygankov
EYE. E. Yagnenkova
E. E. Yagnenkova
VAV. R. Amirova
V. R. Amirova
AMA. S. Mokrova
A. S. Mokrova
Background. Respiratory syncytial virus (RSV) is a common virus causing lower respiratory tract infections (LRTI), including acute bronchiolitis and pneumonia, in children in the first 5 years of life.Objective: to estimate the annual socio-economic burden for the Russian Federation (RF) due to RSV-LRTI in children aged under 5 years.Material and methods. Based on published results of meta-analysis of epidemiological data for RSV-induced infections, the annual number of RSV-LRTI cases, the number of hospitalizations, and associated lethal outcomes were calculated in the model for groups of children aged 0 – <12 months, 12 – <24 months, and 24 – 60 months. The costs of medical care were determined according to the current tariffs of the Compulsory Health Insurance system and published Russian data on the distribution of the number of RSV-LRTI cases by severity. The damage to gross domestic product (GDP) associated with fatalities was estimated taking into account life expectancy and employment.Results. According to the estimates, 397.2 thousand children aged under 5 years in the RF fall ill with RSV-LRTI during a year, including 44.6 thousand cases requiring hospitalization, and in 268 cases, the infection becomes lethal. Medical costs for treatment exceed 2.2 billion rubles, and the damage to GDP as a result of lethal outcomes reaches almost 10 billion rubles. The main damage is related to RSV-LRTI cases in children aged under 1 year, the share of which is over 50% among those hospitalized and over 70% among those who died.Conclusion. RSV significantly affects morbidity and mortality among children aged under 5 years. According to modeling data, it causes up to 3.5% of deaths in this age group, and the associated economic losses exceed 12.2 billion rubles, which justifies the need for RSV-LRTI immunoprophylaxis.

2 November 2022 in Russian Journal of Pediatric Surgery, Anesthesia and Intensive Care
Verified
Journal Article
Open access
PDF file
RIRozaliya G. Idrisova
Rozaliya G. Idrisova
VAViktoria R. Amirova
Viktoria R. Amirova
PMPetr I. Mironov
Petr I. Mironov
ALAndrei U. Lekmanov
Andrei U. Lekmanov
BACKGROUND: A life-threatening organ dysfunction is a strong predictor of in-hospital mortality and adverse outcomes in pediatric patients and full-term neonates. Predictors of outcomes of multiple-organ failure in preterm newborns have not yet been sufficiently determined. AIM: To compare the discriminatory ability of neonatal sequential organ failure (nSOFA) and NEOMOD organ dysfunction scales as predictors of poor outcomes in very preterm newborns. MATERIALS AND METHODS: This prospective observational study included 109 newborns with a birth weight of 1071 (7721451) g and gestational age of 29 (2632) weeks; 22 (20.4%) of them died. RESULTS: The area under the receiver operating characteristic curve was 0.796 (95% confidence interval (CI) 0.7630.827) for the nSOFA scale and 0.771 (95% CI 0.7210.817) for the NEOMOD scale. CONCLUSIONS. Both scales are suitable for measuring the severity of organ dysfunction in preterm newborns. nSOFA appears to predict mortality in preterm newborns.

29 October 2022 in Messenger of ANESTHESIOLOGY AND RESUSCITATION
Verified
Journal Article
Open access
PDF file
PMP. I. Mironov
P. I. Mironov
АLА. U. Lekmanov
А. U. Lekmanov
VAV. R. Amirova
V. R. Amirova
RIR. G. Idrisova
R. G. Idrisova
The objective: to evaluate the applicability of the nSOFA scale as a predictor of an unfavorable outcome in premature newborns.Subjects. The study was designed as retrospective and observational. The study enrolled 109 newborns with a gestational age of ≤ 32 weeks of pregnancy (birth weight 1,071 (772‒1,451) g, gestational age 29 (26‒32) weeks, 22 (20,4%) patients died. nSOFA scores were determined based on the first 72 hours after birth, and a peak values were used for analysis. Death was considered an unfavorable outcome.Results. The nSOFA score > 3 was associated with a odds ratio = 2.5 (CI 1.39–4.64, p = 0.002) for an unfavorable outcome. The area under the ROC curve was 0.796 (95% CI = 0.763–0.827).Conclusion. The nSOFA scale is an acceptable tool for measuring the severity of organ dysfunction and predicting mortality in premature newborns, regardless of the etiology of the disease.

1 January 2024 in Voprosy praktičeskoj pediatrii
Verified
Journal Article
Closed access
VAV.R. Amirova
V.R. Amirova
AGA.A. Greshilov
A.A. Greshilov
ASA.V. Sholokhova
A.V. Sholokhova
Preterm infants born before the 35th week of gestation are at high risk of severe respiratory syncytial virus (RSV) infection. Passive immunoprophylaxis with palivizumab, a monoclonal antibody against RSV, is currently recognized as the most effective measure to prevent RSV infection. The objective of the study was to evaluate the efficacy of prophylactic use of palivizumab in premature infants at high risk of severe RSVI. Patients and methods. A single-center retrospective cohort study conducted on the basis of the Catamnesis Cabinet of the Republican Clinical Perinatal Center (Ufa) included 516 premature children with gestational age less than 35 weeks who reached the age of 1 year of life from April 2020 to April 2022. 250 children were included in the "immunization+" group, and 266 children were included in the "immunization-" group. In both groups, the proportion of children who went to the outpatient clinic for acute respiratory infection (ARI) and the proportion of children hospitalized for lower respiratory tract infection (LRTI) were determined. Results. Among the immunized, the proportion of children presenting to the outpatient clinic for ARI was lower than among the non-immunized, 63.6% and 82.0%, respectively (p < 0.001; OR 0.77; 95% CI 0.69-0.86). There was no statistically significant reduction in the rate of hospitalization of preterm infants due to LRTI overall. However, the proportion of children hospitalized for bronchitis was lower among the immunized than among the non-immunized, 24.0 and 31.6%, respectively (p = 0.045; HR 0.74; 95% CI 0.55-0.99). The greatest effect of palivizumab immunization was observed in children born at 32 weeks' gestation or less who received 3-5 injections of the drug. Conclusion. This study demonstrated the efficacy of immunoprophylaxis with palivizumab in premature infants of the first year of life from the high-risk group of severe RSVI. Key words: respiratory syncytial virus, acute respiratory infection, hospitalization, premature infants, high-risk group, immunoprophylaxis, palivizumab

5 October 2018 in Current Pediatrics
Verified
Journal Article
Open access
PDF file
NKNatalia N. Korableva
Natalia N. Korableva
APAnna A. Plaksina
Anna A. Plaksina
VAVictoria R. Amirova
Victoria R. Amirova
OKOlga Р. Kovtun
Olga Р. Kovtun
SUSergey E. Ukraintsev
Sergey E. Ukraintsev
The results of a questionnaire survey of mothers on the use of infant formulas at the obstetric hospital have been presented. Possible ways to improve the situation with the use of infant formulas in term infants at the obstetric hospital have been discussed. A high frequency of the use of formulas in healthy newborns at the obstetric hospital as well as the practice of issuing formulas as a gift on discharge from the obstetric hospital have been revealed. The literature data has been given on the negative effect of both unreasonable use of formulas and the issuance of formulas as a gift on discharge on the preservation of breastfeeding. It is expected that restricting the distribution of milk formulas without proper indications will lead to an increase in the prevalence of breastfeeding.

18 February 2022 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
NVN.N. Volodin
N.N. Volodin
OHOncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
Aleksei MostovoiAleksei Mostovoi
Aleksei Mostovoi
AKA.L. Karpova
A.L. Karpova
APA.S. Petrova
A.S. Petrova
PCPetrozavodsk Karelia Republican Perinatal Center
Petrozavodsk Karelia Republican Perinatal Center
The aim of the study was to analyze respiratory therapy and the outcomes of nursing preterm infants with gestational age (GA) of less than 32 weeks, who received Beractant in various ways in order to determine the most optimal methods of surfactant administration. Materials and methods of research: a multicenter retrospective cohort study. It was carried out in nine perinatal centers in different regions of the Russian Federation in the period from 07/01/2019 to 06/30/2020. A total of 258 preterm infants with GA of less than 32 weeks participated in the study. One surfactant was used – Beractant (Survant®) at a dose of 100 mg/kg for the first and repeated administration. Beractant was injected by LISA, INSURE or through an endotracheal tube (ETT). Two groups – 1st (154 children) – administration of Beractant via ETT, 2nd (104 children) – minimally invasive surfactant therapy (MIST) of Beractant – combined the LISA and INSURE methods. Two subgroups were identified in the 2nd group: subgroup 2a (27 children) – administration of Beractant by the LISA method, subgroup 2b (77 children) – administration of Beractant by the INSURE method. Results: the ETT and MIST groups were comparable in terms of the median GA (30 versus 30 weeks, p=0.107, respectively) and body weight at birth (1244 versus 1405 g, p=0.067, respectively). In the ETT group in comparison with the MIST group, the administration of Beractant was performed earlier (10 versus 15 min of life, p=0.003, respectively), the need for respiratory support was longer (196.0 versus 120.0 h, p=0.001, respectively), the need for high-frequency oscillatory ventilation was more common (19.7% versus 7.7%, p<0.001, respectively), as well as the need for invasive mechanical ventilation by 72 hours of life (95.4% versus 31.7%, p<0.001, respectively). The incidence of bronchopulmonary dysplasia (BPD) and the length of stay in the intensive care unit and neonatal intensive care unit (NICU) in the ETT group significantly outperformed the MIST group (35.8% versus 13.6%, p<0.001; 10.0 versus 6,0 days, p<0.001, respectively). There were no differences in the frequency of deaths, intraventricular hemorrhages, pneumothoraxes and other complications. The INSURE and LISA subgroups differed in GA and birth weight (30.0 versus 28.0 weeks, p=0.048; 1490.0 versus 1100.0 g, p=0.001, respectively). Conclusions: minimally invasive administration of Beractant significantly reduces the need for invasive respiratory therapy, and, as a result, the incidence of BPD in premature infants with GA of less than 32 weeks.